AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05695079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric fan (high airflow)
Description: Participants are exposed to 36°C, 45% relative humidity for 8 hours without cooling interventions (control condition). Drinking water is available ad libitum. Participants are seated throughout exposure, except for during 10 min periods of simulated activities of daily living (light stepping at 2-2.5 METS) performed at hours 1, 3, 5, and 7. While participants are seated, an electric pedestal fan positioned 1 m away will deliver a continuous airflow of 4 m/s to the front of the body.
Study NCT05182684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vital Patch(TriBell Lab)
Description: Electrocardiograms were recorded using VP-100 for more than six hours and transmitted to a central data server located in Seoul National University Hospital.~The data on a central server was confirmed and evaluated.
Study NCT05521087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75276617
Description: JNJ-75276617 will be administered orally.
Study NCT05521087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine chemotherapy will be administered as intravenous (IV) infusion for participants with AML.
Study NCT06353373 — intervention group
Intervention type: OTHER
Intervention: Application of the modified DeVTEcare system
Description: The modified DeVTEcare system, which incorporates bundled guideline-based VTE prevention measures, will be utilized to assist healthcare providers in VTE prophylaxis after September 2024.
Study NCT05629858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-h Time restricted eating (TRE)
Description: Ad libitum food intake from 1-7 pm every day Fasting from 7-1 pm every day (18-h fast)
Study NCT05629858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Description: 25% energy restriction every day
Study NCT05629858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Usual diet
Study NCT05975593 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tumor collection via biopsy
Description: Cervical cancer: Pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, and recurrence.~Pancreatic cancer: pre-stereotactic body radiotherapy, 12 weeks after completion of radiotherapy, and recurrence.
Study NCT05370040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAHI-SC2 Vaccine
Description: AAHI -SC2 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike protein delivered by nanostructured lipid carrier (NLC) Vaccine
Study NCT05370040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAHI-SC3 Vaccine
Description: AAHI-SC3 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike and nucleocapsid protein delivered by nanostructured lipid carrier (NLC) Vaccine
Study NCT05370040 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: EUA or approved vaccine
Description: Janssen or Pfizer vaccines (control arm)
Study NCT06070467 — intervention group
Intervention type: OTHER
Intervention: Mixed Methods Research (MMR) using quantitative (QUAN) and qualitative (QUAL) tools
Description: A Mixed Methods Research (MMR) using quantitative (QUAN) Vision Related-QoL (VR-QoL = FVQ-CYP and VQoL-CYP) tools and psychosocial PEM-CY, and qualitative (QUAL) socio-anthropologic investigations can capture reliably children's and teenagers' Patient-Reported Outcome (PRO).~The QUAN study is a cross-sectional study including short-term re-test repetition (children/teenagers only) using the following PROMs for children/teenagers:~1. Self-reported questionnaires for patients (FVQ-CYP and VQoL-CYP)~2. For caregivers: PEM-CY questionnaires~The QUAL study will rely on the following instruments:~1. Semi-directive interviews,~2. Focus groups,~3. Field observation.
Study NCT05543616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
Description: Injection in the muscle
Study NCT05543616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose
Description: Injection in the muscle
Study NCT05543616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Description: Injection in the muscle
Study NCT05521087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine chemotherapy will be administered as IV infusion for participants with AML.
Study NCT05521087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Chemotherapy
Description: Intrathecal chemotherapy will be administered as IV infusion for participants with AML or B-cell ALL.
Study NCT05521087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone chemotherapy will be administered as IV infusion for participants with B-cell ALL.
Study NCT05521087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine chemotherapy will be administered as IV infusion for participants with B-cell ALL.
Study NCT05521087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Pegaspargase chemotherapy will be administered as IV infusion for participants with B-cell ALL.
Study NCT05301452 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intravascular Irradiation of Blood (ILIB)
Description: The laser treatment will be performed by a speech therapist and will have the following parameters: wavelength of 808 nm. It will be done twice a week for 8 weeks, in 20-minute sessions.
Study NCT05301452 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intravascular Irradiation of Blood (ILIB)
Description: The photobiomodulation procedure will be simulated, but with the laser turned off. It will be done twice a week for 8 weeks, in 20-minute sessions.
Study NCT05301452 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Orofacial Myofunctional Therapy
Description: Myofunctional therapy will be performed by a speech therapist specialized in the area. It will consist of 1 weekly session, where the functions of breathing, chewing and swallowing will be evaluated and addressed.~The following exercises will be indicated: nasal hygiene, inflated cheeks with the tip of the tongue on the palate, lingual sweep, tongue thrust against the palate, tongue touch on the last molars, chewing of soft solids and bolus assembly (20 minute therapy session).
Study NCT05301452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orofacial Myofunctional Therapy
Description: Myofunctional therapy will be performed by a speech therapist specialized in the area. It will consist of 1 weekly session, where the functions of breathing, chewing and swallowing will be evaluated and addressed.~The following exercises will be indicated: nasal hygiene, inflated cheeks with the tip of the tongue on the palate, lingual sweep, tongue thrust against the palate, tongue touch on the last molars, chewing of soft solids and bolus assembly (20 minute therapy session).
Study NCT04986566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Use standard reporting procedures
Study NCT04986566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Use standard reporting procedures
Study NCT04986566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Use Aetonixx app
Study NCT04986566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Use Aetonixx app
Study NCT04986566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear Vivofit 4
Study NCT04986566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear Vivofit 4
Study NCT04986566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires
Study NCT04986566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires
Study NCT05975593 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Cervical cancer: pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, 6 weeks after completing radiation therapy, 12 weeks after completing radiation therapy, and recurrence.~Pancreatic cancer: pre-stereotactic body radiotherapy, 6 weeks after completion of radiotherapy, 12 weeks after completion of radiotherapy, surgery (if applicable), and recurrence
Study NCT06542185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online education
Description: online education
Study NCT05525637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 20mg
Description: YZJ-1139 20mg tablets, once daily in the evening
Study NCT05525637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 40mg
Description: YZJ-1139 40mg tablets, once daily in the evening
Study NCT05525637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Match placebo tablets, once daily in the evening
Study NCT05975593 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)
Description: Cervical cancer: initial staging, 12 weeks after completing radiation therapy, and recurrence.~Pancreatic cancer: initial staging, stereotactic body radiotherapy (SBRT) simulation, 12 weeks after completing radiation therapy, and recurrence.~The imaging will be performed when possible.
Study NCT04970966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PuraSinus
Description: A randomized ethmoid cavity in the patient will have PuraSinus applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
Study NCT04970966 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioresorbable Nasal Dressing
Description: PosiSep X will be applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
Study NCT05543616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) Substudy A Ph 2/3 Selected Dose
Description: Injection in the muscle
Study NCT04662320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Checkpoint BEST System
Description: Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair.~Other Name: Checkpoint BEST System
Study NCT06030258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: orally taken once daily
Study NCT06030258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: 200mg D1, Q3W, intravenously
Study NCT06030258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg D1, Q3W, intravenously
Study NCT06030258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 5 mg/ml/min, D1, Q3W, intravenously
Study NCT06030258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg/ml/min, D1, Q3W, intravenously
Study NCT06030258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100 mg/m2, D1-D3, Q3W, intravenously
Study NCT06030258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m2, D1-D3, Q3W, intravenously
Study NCT04631341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 5mg every night, for one year
Study NCT06510946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: (Health education program) To increase therapeutic adherence in patients with secondary prevention for cardiovascular disease
Description: The intervention involves a comprehensive health education program based on the Chronic Care Model to increase therapeutic adherence in patients with secondary prevention for cardiovascular disease. The program includes the following components:~Health Education Sessions: Education on the importance of adherence, understanding the disease, side effects of medications, and their management. It addresses personal beliefs and concerns.~Mobile Phone Reminders: Use of alarms and the ti.care® app to remind patients to take their medications.~Medication Verification: Ensuring that the medications and dosages taken match the prescriptions.~Personalized Dosing Systems (PDS): Helping manage medication intake.~Additional Health Advice: Control of other cardiovascular risk factors and benefits of the Mediterranean diet.
Study NCT05722821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive intervention
Description: Hypopressive abdominal gymnastics is based on a basic level hypopressive exercise program that will be:~* A duration of 12 weeks with a frequency of 2 sessions a week and lasting 45 minutes each. Hypopressive abdominal exercises will be performed individually adapted to the capacity of the participant.~* There will be an initial anatomical training of the muscles involved in carrying out the exercise and practice in the respiratory technique for a duration of 15 minutes. Afterwards, hypopressive exercises will begin for 20-30 minutes, changing positions if possible.
Study NCT05804552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dorsal genital nerve stimulation
Description: Two types of stimulation electrodes will be used: UCon Patch Electrodes (InnoCon Medical ApS, Denmark) and ValuTrodes/EconoStim Electrodes (5x5 cm, Axelgaard Manufacturing Co. Ltd., United States). The UCon Patch Electrode acts as a cathode and will be placed on the clitoris. The ValuTrode/EconoStim acts as an anode and will be placed on the lower abdomen. The continuous stimulation consists of a train of single pulses provided continuously with a frequency of 20 Hz and a pulse duration of 200 μs. The burst stimulus pattern consists of a train of bursts. The length of the train is 10 s and will consist of 20-30 bursts/s. One burst consists of 5 identical square pulses (monophasic). The inter-pulse interval is 4 ms (time between the onset of 2 consecutive pulses) while a pulse duration of 200 μs will be used.
Study NCT04726514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SleepFlex
Description: SleepFlex Program
Study NCT04946071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arts-based HIV stigma intervention
Description: The intervention will consist of 2-hour weekly sessions offered to students in participating schools. HIV-related stigma will be addressed by providing key information related to HIV and stigma, facilitating the acquisition of coping skills, and utilizing local cultural practices facilitated by Elders using creative methods to shift existing social and cultural norms that produce and perpetuate stigmatization. Specific intervention activities will include three interrelated activities. The core 2-hour weekly session will cover (1) transformative educational activities; (2) arts-based activities; (3) a summative activity consisting of (3) participatory theatre activites.
Study NCT05031962 — intervention group
Intervention type: DEVICE
Intervention: CELLIS Breast (Porcine Acellular Dermal Matrix, PADM)
Description: Biological membrane used in breast reconstruction
Study NCT04844931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIC + PostC + Standard PCI
Description: RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery
Study NCT04844931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PCI
Description: Standard PCI
Study NCT05810181 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: The following three groups of stakeholders will be interviewed to assess the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases:~(1) patients and families of children with rare genetic diseases who have received gene therapy (to assess their perspectives and understand their informational needs around participating in a clinical trial using gene therapy), (2) patients and families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or ultimately did not qualify for a trial (to elicit feedback and to evaluate whether their informational needs and communication expectations about participating in a clinical trial using gene therapy were met), and (3) healthcare workers who provide care to patients receiving gene therapy (to assess their perspective regarding patient/family needs for gene therapy education and communication).
Study NCT06520878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NANO-PSO (pomegranate seed oil)
Description: NANO-PSO administered orally, 2 capsules, equivalent to 640 mg of pomegranate seed oil, every 24 hours in the morning with food.
Study NCT06520878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally, 2 capsules, equivalent to 640 mg of mineral oil, every 24 hours in the morning with food.
Study NCT06539637 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac}
Description: 10.16 mg/mL (1% w/v) of phenylephrine {Generic Name: Biorphen} (Adrenergic Receptor Agonist) and 2.88 mg/mL (0.3% w/v) of ketorolac {Generic Name: TORADOL} (Nonsteroidal Anti-inflammatory) - via intracameral delivery
Study NCT06539637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine {TORADOL} (0.5%) - Topical Eyedrop
Description: Topical ketorolac tromethamine {TORADOL, Nonsteroidal Anti-inflammatory} (0.5%) administered 4 times daily for the 3 days leading up to surgery. The last drop is to be given at least 2 hours prior to surgery.
Study NCT05039268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC Protein
Description: 3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.
Study NCT06404281 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T-PD-1 Ab cells
Description: Cells will be extracted from a healthy donor, followed by ex-vivo expansion, activation and genetic engineering. The ex-vivo expanded γδ T-PD-1 Ab cells will be adoptively transfused to tumor patients.
Study NCT06390358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tefillin
Description: Wrapping of arm
Study NCT06390358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tefillin
Description: Wrapping of arm
Study NCT05543616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose
Description: Injection in the muscle
Study NCT05543616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose
Description: Injection in the muscle
Study NCT05543616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose
Description: injection in the muscle
Study NCT06111014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latozinemab
Description: All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks
Study NCT05183841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bronchodilator (Ipratropium and Fenoterol)
Description: 8 puffs of Ipratropium (20mcg) and Fenoterol (50mcg) via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
Study NCT06127004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metacognitive Training for Negative Symptoms (MCT)
Description: See arm/group descriptions
Study NCT06127004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counselling
Description: Se arm/group descriptions
Study NCT05500872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-education and blood flow restriction training
Description: Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. During this training, a cuff will be worn from the upper part of the thigh muscles, as in the blood pressure devices, which will slow down the blood flow in the leg. The participant will be cross-educated with the cuff inflated to a safe pressure range that will not cause discomfort. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
Study NCT05500872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-education
Description: Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.